Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

AmerisourceBergen Corporation (ABC - Analyst Report) recently announced that the company has entered into a definitive agreement with Canadian distributor Kohl & Frisch Limited aimed at divesting its Canadian Pharmaceutical Distribution Business.

As per the agreement, AmerisourceBergen Corporation will sell its Canadian pharmaceutical distribution business, AmerisourceBergen Canada Corporation (ABCC) to Kohl & Frisch Limited for approximately $80 million – $100 million. AmerisourceBergen Corporation will hang on to its specialty business unit in Canada.

The performance of the ABCC unit has been disappointing in recent times. On its first quarter fiscal 2013 earnings conference call in Jan 2013, AmerisourceBergen stated that ABCC was having a tough time in implementing a large new retail contract in the Canadian market due to significant reimbursement challenges, particularly for generics.

The transaction is expected to close in the third quarter of fiscal 2013. As a result of the sale, AmerisourceBergen Corporation expects to record an estimated loss on sale and other impairment charges in the range of $160 million and $180 million in the second quarter of fiscal 2013.

Consequently, AmerisourceBergen revised its guidance for 2013. AmerisourceBergen now expects revenues in 2013 to grow by roughly 8% to 10% compared to the previous guidance of 8% – 11%.

AmerisourceBergen increased its earnings guidance in fiscal 2013 to $3.04 – $3.14 from the earlier estimated range of $2.96 – $3.06. The Zacks Consensus Estimate for fiscal 2013 stands at $3.06.

The revised guidance does not include the impact of extraordinary expenses related to the distribution deal signed with Walgreen Company (WAG - Analyst Report) and Alliance Boots GmbH in Mar 2013.

We note that last month AmerisourceBergen entered into a strategic agreement with Walgreen and Alliance Boots GmbH. The agreement includes a 10-year pharmaceutical distribution contract with Walgreens and access to generic drugs and related pharmaceutical products through the Walgreens Boots Alliance Development joint venture.

In return, both Walgreens and Alliance Boots have been granted rights to jointly purchase a minority equity position in AmerisourceBergen.

We note that Walgreens chose AmerisourceBergen over peer Cardinal Health (CAH - Analyst Report) with whom it already had a pharmaceutical distribution contract but decided not to renew the same.

AmerisourceBergen carries a Zacks Rank #3 (Hold). Right now, CVS Caremark Corporation (CVS - Analyst Report) looks well placed with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 33.54 +9.00%
INTERNATIONA ICAGY 33.09 +4.72%
NOAH HOLDING NOAH 13.91 +4.67%
CHINA DISTAN DL 14.79 +4.30%
VALEO SA SPO VLEEY 67.91 +3.95%